STOCK TITAN

[Form 4] Tilray Brands, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Tilray Brands, Inc. (TLRY) – Form 4 filing dated 07/31/2025. Director David F. Clanachan reported two equity events. On 07/30/2025, 124,378 restricted-stock units (RSUs) vested; at the $0.61 reference price the shares converted to common stock (transaction code “M”). To cover withholding taxes, the company retained 65,921 shares (code “F”), leaving the insider with net 58,457 new shares. His direct common-stock holding rises to 170,959 shares after the transactions.

Separately, on 07/29/2025 the director received a new grant of 431,034 RSUs (code “A”). These units vest in one year, subject to continuous service, with accelerated vesting only upon death or disability; voluntary resignation triggers forfeiture. After the grant, Clanachan holds 431,034 unvested RSUs and zero vested units remaining from the prior award.

No open-market purchases or sales occurred, and there is no impact on Tilray’s cash flow or share count beyond ordinary share issuance for equity compensation. The filing primarily signals continued board-level equity alignment rather than a directional view on TLRY’s valuation.

Tilray Brands, Inc. (TLRY) – Comunicazione Form 4 datata 31/07/2025. Il direttore David F. Clanachan ha segnalato due operazioni azionarie. Il 30/07/2025, sono maturate 124.378 unità azionarie vincolate (RSU); al prezzo di riferimento di 0,61$ le azioni sono state convertite in azioni ordinarie (codice transazione “M”). Per coprire le imposte alla fonte, la società ha trattenuto 65.921 azioni (codice “F”), lasciando all’insider un netto di 58.457 nuove azioni. Dopo queste operazioni, la sua posizione diretta in azioni ordinarie sale a 170.959 azioni.

Separatamente, il 29/07/2025 il direttore ha ricevuto una nuova assegnazione di 431.034 RSU (codice “A”). Queste unità maturano in un anno, subordinatamente al servizio continuativo, con maturazione accelerata solo in caso di morte o disabilità; una dimissione volontaria comporta la perdita delle unità. Dopo questa assegnazione, Clanachan detiene 431.034 RSU non maturate e nessuna unità maturata residua dalla precedente assegnazione.

Non si sono verificate operazioni di acquisto o vendita sul mercato aperto, e non vi è alcun impatto sul flusso di cassa o sul numero di azioni di Tilray oltre all’emissione ordinaria di azioni per compensi azionari. La comunicazione indica principalmente un allineamento azionario continuo a livello di consiglio piuttosto che una valutazione direzionale sul valore di TLRY.

Tilray Brands, Inc. (TLRY) – Presentación del Formulario 4 con fecha 31/07/2025. El director David F. Clanachan reportó dos eventos de acciones. El 30/07/2025, se consolidaron 124,378 unidades restringidas de acciones (RSUs); al precio de referencia de $0.61, las acciones se convirtieron en acciones ordinarias (código de transacción “M”). Para cubrir impuestos retenidos, la empresa retuvo 65,921 acciones (código “F”), dejando al insider con 58,457 nuevas acciones netas. Su tenencia directa de acciones ordinarias aumenta a 170,959 acciones tras las transacciones.

Por otro lado, el 29/07/2025 el director recibió una nueva concesión de 431,034 RSUs (código “A”). Estas unidades se consolidan en un año, sujeto a servicio continuo, con consolidación acelerada sólo en caso de muerte o discapacidad; la renuncia voluntaria implica la pérdida de las unidades. Tras la concesión, Clanachan posee 431,034 RSUs no consolidadas y cero unidades consolidadas restantes de la concesión anterior.

No hubo compras ni ventas en el mercado abierto, y no hay impacto en el flujo de caja ni en el número de acciones de Tilray más allá de la emisión ordinaria de acciones para compensación accionaria. La presentación señala principalmente una alineación continua de capital a nivel de junta, más que una visión direccional sobre la valoración de TLRY.

틸레이 브랜드, Inc. (TLRY) – 2025년 7월 31일자 Form 4 제출. 이사 David F. Clanachan이 두 건의 주식 관련 사건을 보고했습니다. 2025년 7월 30일, 124,378개의 제한 주식 단위(RSU)가 성취되었으며, 기준 가격 $0.61로 보통주로 전환되었습니다(거래 코드 “M”). 원천징수세를 충당하기 위해 회사는 65,921주를 보유하였고(코드 “F”), 내부자는 순수 58,457주의 신규 주식을 받았습니다. 이 거래 후 그의 직접 보유 보통주 수는 170,959주로 증가했습니다.

별도로, 2025년 7월 29일 이사는 431,034 RSU 신규 부여(코드 “A”)를 받았습니다. 이 단위들은 1년 후에 성취되며, 지속적인 근무가 조건이고, 사망 또는 장애 시에만 가속 성취됩니다; 자발적 사임 시 단위는 몰수됩니다. 부여 후 Clanachan은 431,034개의 미성취 RSU를 보유하며 이전 수여에서 남은 성취 단위는 없습니다.

공개 시장에서의 매매는 없었고, Tilray의 현금 흐름이나 주식 수에는 주식 보상에 따른 일반적인 주식 발행 외에 영향이 없습니다. 이번 제출은 TLRY의 가치에 대한 방향성보다는 이사회 차원의 지속적인 주식 정렬을 주로 나타냅니다.

Tilray Brands, Inc. (TLRY) – Dépôt du formulaire 4 daté du 31/07/2025. Le directeur David F. Clanachan a signalé deux événements liés aux actions. Le 30/07/2025, 124 378 unités d’actions restreintes (RSU) ont acquis leurs droits ; au prix de référence de 0,61 $, les actions ont été converties en actions ordinaires (code transaction « M »). Pour couvrir les impôts à la source, la société a retenu 65 921 actions (code « F »), laissant à l’initié 58 457 nouvelles actions nettes. Après ces opérations, sa détention directe d’actions ordinaires s’élève à 170 959 actions.

Séparément, le 29/07/2025, le directeur a reçu une nouvelle attribution de 431 034 RSU (code « A »). Ces unités acquièrent leurs droits en un an, sous réserve d’un service continu, avec une acquisition accélérée uniquement en cas de décès ou d’invalidité ; une démission volontaire entraîne la perte des unités. Après cette attribution, Clanachan détient 431 034 RSU non acquises et aucune unité acquise restante de la précédente attribution.

Aucun achat ou vente sur le marché ouvert n’a eu lieu, et il n’y a aucun impact sur la trésorerie ou le nombre d’actions de Tilray au-delà de l’émission ordinaire d’actions pour la rémunération en actions. Le dépôt signale principalement un alignement continu des intérêts au niveau du conseil plutôt qu’une opinion directionnelle sur la valorisation de TLRY.

Tilray Brands, Inc. (TLRY) – Form 4 Einreichung vom 31.07.2025. Direktor David F. Clanachan meldete zwei Aktienereignisse. Am 30.07.2025 wurden 124.378 Restricted Stock Units (RSUs) fällig; zum Referenzpreis von 0,61 $ wurden die Einheiten in Stammaktien umgewandelt (Transaktionscode „M“). Zur Deckung der Quellensteuer behielt das Unternehmen 65.921 Aktien ein (Code „F“), wodurch dem Insider netto 58.457 neue Aktien blieben. Nach den Transaktionen steigt sein direkter Stammaktienbestand auf 170.959 Aktien.

Separat erhielt der Direktor am 29.07.2025 eine neue Zuteilung von 431.034 RSUs (Code „A“). Diese Einheiten werden in einem Jahr fällig, vorbehaltlich kontinuierlicher Dienstzeit, mit beschleunigter Fälligkeit nur im Todes- oder Invaliditätsfall; freiwilliger Rücktritt führt zum Verlust. Nach der Zuteilung hält Clanachan 431.034 nicht fällige RSUs und keine verbleibenden fälligen Einheiten aus der vorherigen Zuteilung.

Es fanden keine Käufe oder Verkäufe am freien Markt statt, und es gibt keine Auswirkungen auf Tilrays Cashflow oder Aktienanzahl über die gewöhnliche Aktienausgabe zur Aktienvergütung hinaus. Die Einreichung signalisiert hauptsächlich eine fortgesetzte Aktienausrichtung auf Vorstandsebene und keine richtungsweisende Einschätzung der TLRY-Bewertung.

Positive
  • Director increases direct share ownership by net 58,457 shares, signalling continued personal stake in TLRY.
  • New 431,034-share RSU grant aligns board incentives with shareholder value creation.
Negative
  • Share-settled tax withholding adds minor dilution and indicates no cash outlay by insider.
  • No open-market purchase; transaction does not convey bullish conviction on stock price.

Insights

TL;DR: Routine RSU vesting and new grant; no open-market activity, neutral for valuation.

The director’s transactions are compensation-related. Net share addition of 58.5k is immaterial (<0.05 % of basic shares). New 431k RSU grant aligns incentives but introduces potential future dilution of roughly 0.06 % once vested—insignificant versus Tilray’s 740 m shares outstanding. Absence of insider buying or selling suggests no distinct signal on near-term fundamentals. Overall market impact should be negligible.

TL;DR: Equity compensation reinforces board alignment; standard practice, marginal dilution.

The one-year cliff vesting encourages short-term retention, while accelerated vesting only for death/disability limits windfalls. Tax-withholding via share surrender is routine and avoids cash payout. Grant size is consistent with mid-cap cannabis peers. No red flags on compliance—Form 4 filed promptly and signed by attorney-in-fact. Investors should view this as normal governance housekeeping rather than a strategic event.

Tilray Brands, Inc. (TLRY) – Comunicazione Form 4 datata 31/07/2025. Il direttore David F. Clanachan ha segnalato due operazioni azionarie. Il 30/07/2025, sono maturate 124.378 unità azionarie vincolate (RSU); al prezzo di riferimento di 0,61$ le azioni sono state convertite in azioni ordinarie (codice transazione “M”). Per coprire le imposte alla fonte, la società ha trattenuto 65.921 azioni (codice “F”), lasciando all’insider un netto di 58.457 nuove azioni. Dopo queste operazioni, la sua posizione diretta in azioni ordinarie sale a 170.959 azioni.

Separatamente, il 29/07/2025 il direttore ha ricevuto una nuova assegnazione di 431.034 RSU (codice “A”). Queste unità maturano in un anno, subordinatamente al servizio continuativo, con maturazione accelerata solo in caso di morte o disabilità; una dimissione volontaria comporta la perdita delle unità. Dopo questa assegnazione, Clanachan detiene 431.034 RSU non maturate e nessuna unità maturata residua dalla precedente assegnazione.

Non si sono verificate operazioni di acquisto o vendita sul mercato aperto, e non vi è alcun impatto sul flusso di cassa o sul numero di azioni di Tilray oltre all’emissione ordinaria di azioni per compensi azionari. La comunicazione indica principalmente un allineamento azionario continuo a livello di consiglio piuttosto che una valutazione direzionale sul valore di TLRY.

Tilray Brands, Inc. (TLRY) – Presentación del Formulario 4 con fecha 31/07/2025. El director David F. Clanachan reportó dos eventos de acciones. El 30/07/2025, se consolidaron 124,378 unidades restringidas de acciones (RSUs); al precio de referencia de $0.61, las acciones se convirtieron en acciones ordinarias (código de transacción “M”). Para cubrir impuestos retenidos, la empresa retuvo 65,921 acciones (código “F”), dejando al insider con 58,457 nuevas acciones netas. Su tenencia directa de acciones ordinarias aumenta a 170,959 acciones tras las transacciones.

Por otro lado, el 29/07/2025 el director recibió una nueva concesión de 431,034 RSUs (código “A”). Estas unidades se consolidan en un año, sujeto a servicio continuo, con consolidación acelerada sólo en caso de muerte o discapacidad; la renuncia voluntaria implica la pérdida de las unidades. Tras la concesión, Clanachan posee 431,034 RSUs no consolidadas y cero unidades consolidadas restantes de la concesión anterior.

No hubo compras ni ventas en el mercado abierto, y no hay impacto en el flujo de caja ni en el número de acciones de Tilray más allá de la emisión ordinaria de acciones para compensación accionaria. La presentación señala principalmente una alineación continua de capital a nivel de junta, más que una visión direccional sobre la valoración de TLRY.

틸레이 브랜드, Inc. (TLRY) – 2025년 7월 31일자 Form 4 제출. 이사 David F. Clanachan이 두 건의 주식 관련 사건을 보고했습니다. 2025년 7월 30일, 124,378개의 제한 주식 단위(RSU)가 성취되었으며, 기준 가격 $0.61로 보통주로 전환되었습니다(거래 코드 “M”). 원천징수세를 충당하기 위해 회사는 65,921주를 보유하였고(코드 “F”), 내부자는 순수 58,457주의 신규 주식을 받았습니다. 이 거래 후 그의 직접 보유 보통주 수는 170,959주로 증가했습니다.

별도로, 2025년 7월 29일 이사는 431,034 RSU 신규 부여(코드 “A”)를 받았습니다. 이 단위들은 1년 후에 성취되며, 지속적인 근무가 조건이고, 사망 또는 장애 시에만 가속 성취됩니다; 자발적 사임 시 단위는 몰수됩니다. 부여 후 Clanachan은 431,034개의 미성취 RSU를 보유하며 이전 수여에서 남은 성취 단위는 없습니다.

공개 시장에서의 매매는 없었고, Tilray의 현금 흐름이나 주식 수에는 주식 보상에 따른 일반적인 주식 발행 외에 영향이 없습니다. 이번 제출은 TLRY의 가치에 대한 방향성보다는 이사회 차원의 지속적인 주식 정렬을 주로 나타냅니다.

Tilray Brands, Inc. (TLRY) – Dépôt du formulaire 4 daté du 31/07/2025. Le directeur David F. Clanachan a signalé deux événements liés aux actions. Le 30/07/2025, 124 378 unités d’actions restreintes (RSU) ont acquis leurs droits ; au prix de référence de 0,61 $, les actions ont été converties en actions ordinaires (code transaction « M »). Pour couvrir les impôts à la source, la société a retenu 65 921 actions (code « F »), laissant à l’initié 58 457 nouvelles actions nettes. Après ces opérations, sa détention directe d’actions ordinaires s’élève à 170 959 actions.

Séparément, le 29/07/2025, le directeur a reçu une nouvelle attribution de 431 034 RSU (code « A »). Ces unités acquièrent leurs droits en un an, sous réserve d’un service continu, avec une acquisition accélérée uniquement en cas de décès ou d’invalidité ; une démission volontaire entraîne la perte des unités. Après cette attribution, Clanachan détient 431 034 RSU non acquises et aucune unité acquise restante de la précédente attribution.

Aucun achat ou vente sur le marché ouvert n’a eu lieu, et il n’y a aucun impact sur la trésorerie ou le nombre d’actions de Tilray au-delà de l’émission ordinaire d’actions pour la rémunération en actions. Le dépôt signale principalement un alignement continu des intérêts au niveau du conseil plutôt qu’une opinion directionnelle sur la valorisation de TLRY.

Tilray Brands, Inc. (TLRY) – Form 4 Einreichung vom 31.07.2025. Direktor David F. Clanachan meldete zwei Aktienereignisse. Am 30.07.2025 wurden 124.378 Restricted Stock Units (RSUs) fällig; zum Referenzpreis von 0,61 $ wurden die Einheiten in Stammaktien umgewandelt (Transaktionscode „M“). Zur Deckung der Quellensteuer behielt das Unternehmen 65.921 Aktien ein (Code „F“), wodurch dem Insider netto 58.457 neue Aktien blieben. Nach den Transaktionen steigt sein direkter Stammaktienbestand auf 170.959 Aktien.

Separat erhielt der Direktor am 29.07.2025 eine neue Zuteilung von 431.034 RSUs (Code „A“). Diese Einheiten werden in einem Jahr fällig, vorbehaltlich kontinuierlicher Dienstzeit, mit beschleunigter Fälligkeit nur im Todes- oder Invaliditätsfall; freiwilliger Rücktritt führt zum Verlust. Nach der Zuteilung hält Clanachan 431.034 nicht fällige RSUs und keine verbleibenden fälligen Einheiten aus der vorherigen Zuteilung.

Es fanden keine Käufe oder Verkäufe am freien Markt statt, und es gibt keine Auswirkungen auf Tilrays Cashflow oder Aktienanzahl über die gewöhnliche Aktienausgabe zur Aktienvergütung hinaus. Die Einreichung signalisiert hauptsächlich eine fortgesetzte Aktienausrichtung auf Vorstandsebene und keine richtungsweisende Einschätzung der TLRY-Bewertung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Clanachan David F

(Last) (First) (Middle)
C/O TILRAY BRANDS, INC.
265 TALBOT STREET WEST

(Street)
LEAMINGTON A6 N8H 4H3

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tilray Brands, Inc. [ TLRY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/30/2025 M 124,378(1) A $0.61 236,880(3) D
Common Stock 07/30/2025 F 65,921(2) D $0.61 170,959(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (4) 07/30/2025 M 124,378 (5) (5) Common Stock 124,378 $0 0(6) D
Restricted Stock Units (4) 07/29/2025 A 431,034 (5) (5) Common Stock 431,034 $0 431,034(6) D
Explanation of Responses:
1. On July 30, 2025, a total of 124,378 RSUs vested. Each RSU represents a contingent right to receive one (1) share of Tilray Common Stock.
2. Represents shares withheld by the Company to satisfy the tax withholding obligation associated with the vesting of 124,378 LTIP RSUs previously granted on July 30, 2024.
3. Amount includes shares of Common Stock beneficially owned by the reporting person, but excludes other unvested RSUs.
4. Each restricted stock unit represents a contingent right to receive one (1) share of Tilray Common Stock.
5. Subject to the reporting person's continuous service, the restricted stock units shall vest one year from the date of grant, with accelerated vesting solely upon death or disability prior to such date. In the event of a voluntary resignation by the reporting person prior to the vesting date, all restricted stock units will be forfeited.
6. Amount represents the total amount of unvested RSUs and underlying shares of Tilray Common Stock.
/s/ Carl A. Merton, as Attorney-in-Fact for David Clanachan 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Tilray (TLRY) shares did Director David Clanachan acquire on 07/30/2025?

He received 124,378 shares from RSU vesting, of which 65,921 were withheld for taxes, leaving 58,457 net shares added to his holdings.

What is David Clanachan's total direct ownership after the Form 4 transactions?

The director now directly owns 170,959 Tilray common shares plus 431,034 unvested RSUs.

Did the insider sell any Tilray shares on the open market?

No. All reported share movements were internal—RSU vesting and tax withholding—with no open-market sales or purchases.

What are the vesting terms for the newly granted 431,034 RSUs?

They vest one year from the 07/29/2025 grant date, subject to continuous service, with acceleration only upon death or disability.

Will the RSU grant cause significant dilution for Tilray shareholders?

The potential dilution is approximately 0.06 % of Tilray’s outstanding shares, a minimal impact.
TILRAY BRANDS INC

NASDAQ:TLRY

TLRY Rankings

TLRY Latest News

TLRY Latest SEC Filings

TLRY Stock Data

672.74M
1.02B
0.65%
11.72%
17.36%
Drug Manufacturers - Specialty & Generic
Medicinal Chemicals & Botanical Products
Link
Canada
NEW YORK